Gilead Sciences has an amazing track record of bringing game-changing new drugs to market. Could this unique ability also be the company's biggest weakness?
Bristol-Myers Squibb's hepatitis C sales topped AbbVie's in the first quarter. Is this trend set to continue?
Biopharma stocks are starting to pull back in a big way. Flamel Technologies and Pfizer, though, are two good names to pick up on any weakness. Here's why.
Bristol-Myers posts a much stronger first quarter than expected. Here's what investors need to know.
The generic-drug market is sizzling hot. Here are three investing ideas to catch some of that heat wave.
Bristol-Myers Squibb is pinning its future on a new class of drugs that could be game-changers in the fight against cancer. The Street, though, may be wildly overestimating their commercial potential. Here's why.
Eagle Pharmaceuticals Inc., Esperion Therapeutics Inc., and Horizon Pharma plc have more than doubled investors' money this year.
In the multibillion-dollar market for hepatitis C, this company stands above the crowd.
Despite the threat of patent losses, our analysts believe these Big Pharma stocks would be smart investments over the next 20 years.
Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?